Adaptive Biotech

Adaptive Biotechnologies is a pioneer & leader in immune-driven medicine. We aim to improve lives by learning from the wisdom of our adaptive immune systems.

[Adaptive Biotech @AdaptiveBiotech]

September is #BloodCancerAwarenessMonth. According to @BloodCancerUtd, every 3 minutes someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma. At Adaptive, we’re committed to deeper insight and more informed decisions across the blood cancer journey.

[Adaptive Biotech @AdaptiveBiotech]

Adaptive has been named a U.S. News & World Report 2026–2027 Best Company to Work For across four categories. We couldn’t be prouder. https://t.co/kOQea0gHkz

#BeAdaptive #BestCompanies

[Adaptive Biotech @AdaptiveBiotech]

This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to learn why Chris, Christine and Amanda #Obliteride. #BeAdaptive

[Adaptive Biotech @AdaptiveBiotech]

clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.

[Adaptive Biotech @AdaptiveBiotech]

The road to @Obliteride is about more than race day—it's about coming together for a shared purpose. Adaptive teammates have hosted group trainings and rides rallying fundraising support for lifesaving cancer research. #Obliteride #BeAdaptive #CureCancerFaster #TeamAdaptive

[Adaptive Biotech @AdaptiveBiotech]

As MRD adoption accelerates, clinical practice is evolving—especially in the community.

🎥 Jay Patel, Dir., Medical Affairs, on how clonoSEQ® is being leveraged in the community setting

[Adaptive Biotech @AdaptiveBiotech]

As a leader within PRIDE @ Adaptive, Kirsten Wollam helps advance initiatives that strengthen inclusion, representation, and support for LGBTQ+ employees across our company.

#PrideMonth #BeAdaptive #InclusionAndBelonging

[Adaptive Biotech @AdaptiveBiotech]

As MRD moves into routine care, what matters most is having an approach that is deeply validated, highly sensitive and specific, and widely adopted across both clinical trials and real-world practice.

🎥 Hear more from Mary Pat Lancelotta, SVP MRD Biopharma

[Adaptive Biotech @AdaptiveBiotech]

Data at #ASCO2026 and #EHA2026 reinforce clonoSEQ’s role as a gold standard for assessing depth of response, longitudinal disease monitoring, and MRD-guided treatment decision-making. Explore more than 30 abstracts featuring clonoSEQ across both meetings: https://t.co/AKC0JuujkL

[Adaptive Biotech @AdaptiveBiotech]

Launch your next molecular #immuneprofiling study in days — not weeks.

Adaptive has partnered with @scientist_com — giving you a faster path from idea to actionable #TCR and #BCR deep sequencing results.

Start your project today. https://t.co/FEf7PLLOBS

[Adaptive Biotech @AdaptiveBiotech]

What happens when models learn directly from large-scale T cell activation data?

In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. https://t.co/6vHMxrAzHZ

#worldimmunologyday

[Adaptive Biotech @AdaptiveBiotech]

How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at #ML4H2025) explores a data-driven approach using large-scale T-cell activation data. Read more: https://t.co/6vHMxrAzHZ

[Adaptive Biotech @AdaptiveBiotech]

Adaptive is attending #AACR26.

We partner with biopharma teams using T- and B-cell receptor sequencing and MRD testing to advance hematology and oncology research and clinical trials.

Let’s talk about your study.
📩 [email protected]

[Adaptive Biotech @AdaptiveBiotech]

ICYMI: Adaptive's latest webinar highlights how our TCR and BCR sequencing technologies and large-scale immune repertoire database can accelerate the development of immune-modulating therapies.

🎧 Access the recording now: https://t.co/mdURjXkknV

[Adaptive Biotech @AdaptiveBiotech]

This #MyelomaAwarenessMonth, hear from Allison Jacob, VP Medical Affairs, how MRD testing is informing care decisions across the myeloma journey. Adaptive is working to help bring better outcomes to people living with lymphoid malignancies.

[Adaptive Biotech @AdaptiveBiotech]

There’s still time to register for our March 18 webinar ⏰

Learn how immunosequencing and large scale immune data drive smarter R&D decisions—from MoA validation to PK/PD and TCR signal detection.

👉 Register: https://t.co/vU08QdctxI

[Adaptive Biotech @AdaptiveBiotech]

This #IWD2026, Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.” #GiveToGain #BeAdaptive

[Adaptive Biotech @AdaptiveBiotech]

March is Myeloma Action Month. 🩸

Taking action starts with awareness. Understanding what remains can change what comes next.

#MyelomaActionMonth #MoreThanMyeloma

[Adaptive Biotech @AdaptiveBiotech]

Last week, we came together to celebrate #BlackHistoryMonth and welcome the #YearoftheHorse with shared traditions, a festive raffle and bake sale. We proudly raised funds to support the William Grose Center for Cultural Innovation in Seattle’s Central District.

[Adaptive Biotech @AdaptiveBiotech]

New Adaptive research, featured in @DrugDiscovNews, shows how T-cell receptor sequencing can identify shared, celiac-associated immune signatures in blood—highlighting the potential for a noninvasive approach to studying and monitoring celiac disease.🔗 https://t.co/Gv3CsgE3Az